Strategy & Advisory

Ophthalmic sponsors routinely face decisions that bind capital for years: which indication to advance first, whether to pursue regional partnerships, and how to position an asset for the next financing or governance milestone. Strategy advisory at BEEÑA-E is built for those decisions — not generic market landscaping.

We assess programs through an integrated lens: mechanism and clinical differentiation, regulatory precedents in retina, cornea, and rare ophthalmic disease, competitive timelines, and the operational requirements of global development. Outputs are designed for executive committees, boards, and transaction counterparties who expect defensible assumptions.

Typical engagements include indication prioritization under capital constraints, asset and portfolio valuations for BD and licensing, alliance structuring support, and preparation of board- and investor-ready narratives. We also advise on scientific advisory committee preparation and external expert alignment where independent ophthalmic judgment is required.

Our advisors have supported multi-asset gene therapy portfolios, first-in-class biologics, and platform technologies across US and EU footprints. We emphasize traceable logic, explicit trade-offs, and alignment with downstream regulatory, clinical, and access planning — so strategy does not live in isolation from execution.